相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
A. El-Khoueiry et al.
ANNALS OF ONCOLOGY (2020)
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis
Kazuya Kariyama et al.
LIVER CANCER (2020)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use
Yuan-Hung Kuo et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
Atsushi Hiraoka et al.
LIVER CANCER (2017)
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma
Julien Edeline et al.
LIVER INTERNATIONAL (2016)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
分享论文
